Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026

MindRank, a clinical-stage AI-native drug discovery company, announced the completion of a $52 million Series...

Company Drug

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

Fineline Cube Jul 8, 2026

Shanghai Stexo Biotechnology Co., Ltd. announced that its proprietary extracellular vesicle drug STX11101 injection, derived...

Others

Biocytogen and Whitehawk Forge Global BsADC Partnership to Accelerate Next-Generation Cancer Therapies

Fineline Cube Jul 8, 2026

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) and Whitehawk Therapeutics, Inc. (NASDAQ: WHWK)...

Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026

Sino Biopharmaceutical Limited (HKG: 1177) announced an expanded strategic partnership with GlaxoSmithKline plc (GSK, NYSE:...

Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026

China’s National Medical Products Administration (NMPA), in coordination with the Ministry of Public Security and...

Drug Policy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

Fineline Cube Jul 7, 2026

China’s National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) unveiled the “PIONEER” (Propel...

Company Deals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

Fineline Cube Jul 7, 2026

Immunocon and MabGalaxy announced a comprehensive upgrade of their strategic cooperation, integrating artificial intelligence and...

Company Deals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

Fineline Cube Jul 7, 2026

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) announced a definitive acquisition...

Company Deals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

Fineline Cube Jul 7, 2026

Hainan Shuangcheng Pharmaceutical Co., Ltd. (SHE: 002693) announced an exclusive licensing agreement with undisclosed American...

Company Deals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

Fineline Cube Jul 7, 2026

CStone Pharmaceuticals (HKG: 2616) announced an exclusive commercialization partnership with Arrotex Pharmaceuticals Pty Ltd, the...

Company Deals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Fineline Cube Jul 7, 2026

Serapha Bio announced a transformative series of transactions including an exclusive worldwide license from YolTech...

Company Deals

Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets

Fineline Cube Jul 7, 2026

Alphamab Oncology (HKG: 9966) announced a strategic cooperation agreement with Russian biopharmaceutical company LLC Nanolek,...

Company Deals

TrueLab Biopharmaceutical, Bionyra Pharma Forge $985M TL1A Antibody Deal with Dual IBD Candidates

Fineline Cube Jul 7, 2026

TrueLab Biopharmaceutical announced an exclusive license agreement with newly launched clinical-stage company Bionyra Pharma, granting...

Company Medical Device

Shanghai ZJ Bio-Tech Ebola Detection Kit Receives WHO Emergency Use Listing for Bundibugyo Strain

Fineline Cube Jul 7, 2026

Shanghai ZJ Bio-Tech Co., Ltd. (SHA: 688317) announced that its Ebola Virus Nucleic Acid Detection...

Company Deals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

Fineline Cube Jul 7, 2026

cAMPfield Therapeutics, Inc. announced its official launch alongside the completion of a $180 million Series...

Company Deals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology

Fineline Cube Jul 7, 2026

BriSTAR Immunotech (Beijing) Co., Ltd. announced the completion of a Series C financing round exceeding...

Company Deals

Formosa Pharmaceuticals, Samil Pharma Expand Partnership with APP13007 Vietnam Licensing Deal

Fineline Cube Jul 7, 2026

Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with South Korea’s Samil Pharmaceuticals, Co.,...

Company Deals

Carephar Pharmaceutical, Silk Road Medical Forge Central Asia Deal for Keverprazan P-CAB Innovation

Fineline Cube Jul 7, 2026

Jiangsu Carephar Pharmaceutical Co., Ltd. and Silk Road Medical Technology announced a strategic cooperation agreement...

Policy / Regulatory

Guangdong Launches “Spring Rain Action” to Accelerate Medical Device Innovation Transformation with 900+ Clinical Achievements Target

Fineline Cube Jul 7, 2026

The Guangdong Provincial Medical Products Administration, in collaboration with the Department of Industry and Information...

Company Deals

Astex Pharmaceuticals, Genentech Forge $515M Breast Cancer Small Molecule Drug Collaboration

Fineline Cube Jul 7, 2026

Astex Pharmaceuticals announced an exclusive, worldwide research collaboration and license agreement with Genentech, a member...

Posts pagination

1 … 26 27 28 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.